Haleon Cuts Outlook on Weak Flu Medicine Demand and China Woes

Haleon announced a reduction in its full-year organic revenue growth guidance to approximately 2.5%, compared to the 3% to 5% range previously communicated during its half-year results in July. The company attributed this downward revision to weaker performance in its cough, cold, and flu product portfolio, particularly due to lower order volumes in North America. While the respiratory health category experienced a 2% decline in organic revenue, the company noted growth in other areas, such as an 8.8% organic increase in its oral health category.